Reduction of choroidal neovascularization in mice by adeno-associated virus-delivered anti-vascular endothelial growth factor short hairpin RNA

Journal of Gene Medicine

Volumn 14, Issue 11, 2012, Pages 632-641

  Askou, Anne Louise ^a   Pournaras, Jean Antoine C ^b   Pihlmann, Maria ^a   Svalgaard, Jesper D ^a   Arsenijevic, Yvan ^b   Kostic, Corinne ^b   Bek, Toke ^c   Dagnæs Hansen, Frederik ^a   Mikkelsen, Jacob Giehm ^a   Jensen, Thomas Gryesten ^a   Corydon, Thomas J ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adeno associated virus; AMD; Angiogenesis; Anti VEGF gene therapy; Choroidal neovascularization; Short hairpin RNA

Indexed keywords

PARVOVIRUS VECTOR; SHORT HAIRPIN RNA; VASCULOTROPIN INHIBITOR;

ADENO ASSOCIATED VIRUS; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; IN VIVO STUDY; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PLASMID; PRIORITY JOURNAL; SEROTYPE; SUBRETINAL NEOVASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

ANIMALS; CELL LINE; CHOROIDAL NEOVASCULARIZATION; DEPENDOVIRUS; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RETINAL PIGMENT EPITHELIUM; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MIRIDAE; MURINAE; MUS; RENILLA LUCIFERASE;

EID: 84869753952     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2678     Document Type: Article

References (47)

1. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
2. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
3. Colquitt JL, Jones J, Tan SC, et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2008; 12: iii-iv, ix-201.
4. Tezel TH, Bora NS, Kaplan HJ. Pathogenesis of age-related macular degeneration. Trends Mol Med 2004; 10: 417-420.
5. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000; 157: 135-144.
6. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Brit J Ophthalmol 1997; 81: 154-162.
7. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab vs. verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
8. Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005; 12: 1072-1082.
9. Min SH, Molday LL, Seeliger MW, et al. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis. Mol Ther 2005; 12: 644-651.
10. Tschernutter M, Schlichtenbrede FC, Howe S, et al. Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy. Gene Ther 2005; 12: 694-701.
11. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231-2239.
12. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-2248.
13. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008; 19: 979-990.
14. Mao Y, Kiss S, Boyer JL, et al. Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab. Hum Gene Ther 2011; 22: 1525-1535.
15. Maclachlan TK, Lukason M, Collins M, et al. Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther 2011; 19: 326-334.
16. Lai CM, Estcourt MJ, Wikstrom M, et al. rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Invest Ophthalmol Vis Sci 2009; 50: 4279-4287.
17. Chadderton N, Millington-Ward S, Palfi A, et al. Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol Ther 2009; 17: 593-599.
18. Yuan MK, Tao Y, Yu WZ, et al. Lentivirus-mediated RNA interference of vascular endothelial growth factor in monkey eyes with iris neovascularization. Mol Vis 2010; 16: 1743-1753.
19. Singerman L. Combination therapy using the small interfering RNA bevasiranib. Retina 2009; 29: S49-S50.
20. Paskowitz DM, Greenberg KP, Yasumura D, et al. Rapid and stable knockdown of an endogenous gene in retinal pigment epithelium. Hum Gene Ther 2007; 18: 871-880.
21. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44: 2155-2162.
22. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003; 198: 483-489.
23. Pihlmann M, Askou AL, Aagaard L, et al. Adeno-associated virus-delivered polycistronic microRNA-clusters for knockdown of vascular endothelial growth factor in vivo. J Gene Med 2012; 14: 328-338.
24. Winer J, Jung CK, Shackel I, et al. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 1999; 270: 41-49.
25. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
26. Bemelmans AP, Kostic C, Crippa SV, et al. Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis. PLoS Med 2006; 3: e347.
27. Jakobsen M, Stenderup K, Rosada C, et al. Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model. Mol Ther 2009; 17: 1743-1753.
28. Kostic C, Chiodini F, Salmon P, et al. Activity analysis of housekeeping promoters using self-inactivating lentiviral vector delivery into the mouse retina. Gene Ther 2003; 10: 818-821.
29. Clark ML, Fowler JA, Penn JS. Animal Models of Choroidal Neovascularization In Animal Models of Choroidal Neovascularization (Retinal and Choroidal Angiogenesis), Penn JS (ed). Springer: The Netherlands, 2008.
30. Tobe T, Ortega S, Luna JD, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 1998; 153: 1641-1646.
31. Ng YS, Rohan R, Sunday ME, et al. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 2001; 220: 112-121.
32. Mussolino C, Della Corte M, Rossi S, et al. AAV-mediated photoreceptor transduction of the pig cone-enriched retina. Gene Ther 2011; 18: 637-645.
33. Kostic C, Crippa SV, Pignat V, et al. Gene therapy regenerates protein expression in cone photoreceptors in Rpe65(R91 W/R91 W) mice. PLoS One 2011; 6: e16588.
34. Dinculescu A, Glushakova L, Min SH, et al. Adeno-associated virus-vectored gene therapy for retinal disease. Hum Gene Ther 2005; 16: 649-663.
35. Justilien V, Pang JJ, Renganathan K, et al. SOD2 knockdown mouse model of early AMD. Invest Ophthalmol Vis Sci 2007; 48: 4407-4420.
36. Stieger K, Colle MA, Dubreil L, et al. Subretinal delivery of recombinant AAV serotype 8 vector in dogs results in gene transfer to neurons in the brain. Mol Ther 2008; 16: 916-923.
37. Natkunarajah M, Trittibach P, McIntosh J, et al. Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene Ther 2008; 15: 463-467.
38. Allocca M, Mussolino C, Garcia-Hoyos M, et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol 2007; 81: 11372-11380.
39. Vandenberghe LH, Bell P, Maguire AM, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.
40. Bora PS, Hu Z, Tezel TH, et al. Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proc Natl Acad Sci USA 2003; 100: 2679-2684.
41. Yokoi K, Kachi S, Zhang HS, et al. Ocular gene transfer with self-complementary AAV vectors. Invest Ophthalmol Vis Sci 2007; 48: 3324-3328.
42. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5years after vector administration. Mol Ther 2010; 18: 643-650.
43. Cashman SM, Bowman L, Christofferson J, et al. Inhibition of choroidal neovascularization by adenovirus-mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD. Invest Ophthalmol Vis Sci 2006; 47: 3496-3504.
44. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012; 4: 120ra115.
45. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-216.
46. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13: 225-234.
47. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452: 591-597.